drugset
drugset / Trial / NCT00240071

Study of Avastin (Bevacizumab) to Reverse Acquired Estrogen Independence in Previously Hormone Responsive Metastatic Breast Ca.

NCT00240071 ↗

Phase 2 Completed 30 enrolled University of Alabama at Birmingham Genentech, Inc. · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine if acquired hormone therapy resistance can be reversed by Avastin (Bevacizumab), as measured by time to disease progression and evaluate toxicity of the combination of hormone treatment plus Avastin (Bevacizumab).

Timeline

Start
2005-10
Primary completion
2009-03
Completion
2011-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Bevacizumab Monoclonal antibody 15 mg/kg Intravenous
Background Anastrozole Other / unclassified 1 mg Oral
Background Exemestane Small molecule 25 mg Oral
Background Letrozole Other / unclassified 2.5 mg Oral
Background Tamoxifen Small molecule 20 mg Oral

Indications

breast cancer